| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Eupalinolide O targets cancer cells and inflammatory pathways. It induces cell cycle arrest and apoptosis in human MDA-MB-468 breast cancer cells. The compound exerts its anti-inflammatory and anticancer effects primarily through the inhibition of NF-κB signaling. Its ability to modulate key cellular pathways, including NF-κB, makes it a promising candidate for drug development targeting inflammation-related diseases and malignancies. The reactive α-methylene-γ-lactone moiety is thought to be responsible for its biological activity.
|
|---|---|
| ln Vitro |
In human MDA-MB-468 breast cancer cells, eupalinolide O may cause cell cycle arrest and apoptosis. The human MDA-MB-468 breast cancer cells exhibit anti-TNBC (triple-negative breast cancer) action when exposed to eupalinolide O [1].
In vitro, Eupalinolide O induces cell cycle arrest and apoptosis in human MDA-MB-468 breast cancer cells. It demonstrates significant anticancer activity through the inhibition of NF-κB signaling and induction of apoptosis. The compound's ability to induce apoptosis in cancer cells makes it a valuable tool for studying cancer biology and developing anticancer therapies. These in vitro activities support its potential as an anticancer agent. |
| ln Vivo |
In vivo data for Eupalinolide O is limited in publicly available sources. As a sesquiterpene lactone with potent in vitro anticancer activity, the compound is expected to have potential applications in animal models of breast cancer and other malignancies. However, specific published in vivo efficacy studies are not widely reported. Eupalinolide O is primarily used as a research compound for studying anticancer mechanisms and natural product pharmacology.
|
| Enzyme Assay |
The in vitro apoptosis assay for Eupalinolide O is conducted in human MDA-MB-468 breast cancer cells. Cells are treated with varying concentrations of the compound for 24-72 hours. Apoptosis is measured by flow cytometry using Annexin V/PI staining, caspase activity assays, and detection of DNA fragmentation. Cell cycle analysis is performed by flow cytometry. NF-κB signaling is assessed by measuring NF-κB activity using reporter gene assays or by Western blotting for phosphorylated NF-κB and downstream targets.
|
| Cell Assay |
Cellular assays for Eupalinolide O are conducted in human MDA-MB-468 breast cancer cells and other cancer cell lines. Cells are treated with varying concentrations of the compound for 24-72 hours. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. Apoptosis is assessed by flow cytometry, caspase activity, and DNA fragmentation. Cell cycle distribution is analyzed by flow cytometry. NF-κB activity is measured using reporter gene assays or Western blotting.
|
| Animal Protocol |
In vivo studies for Eupalinolide O would typically involve xenograft mouse models of breast cancer or other malignancies. The compound would be administered via intraperitoneal or oral routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring tumor growth inhibition, with pharmacodynamic markers such as apoptosis and NF-κB signaling evaluated in tumor tissues. However, specific published in vivo protocols for Eupalinolide O are not available in the current literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Eupalinolide O is not extensively reported in publicly available sources. The compound has a molecular weight of 418.44 g/mol and a molecular formula of C₂₂H₂₆O₈. It is soluble in DMSO. As a sesquiterpene lactone, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available in the current literature for this research compound. Storage conditions are typically at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for Eupalinolide O is limited in publicly available sources. As with all research compounds, Eupalinolide O is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays in normal cell lines and in vivo tolerability studies would be required for a complete toxicity assessment. No specific toxicity data has been reported in the available literature for this compound.
|
| References | |
| Additional Infomation |
Eupalinolide O is a sesquiterpene lactone isolated from Eupatorium lindleyanum, traditionally used in Chinese medicine. It features a germacranolide skeleton with reactive α-methylene-γ-lactone and epoxide moieties. Eupalinolide O demonstrates significant anti-inflammatory and anticancer properties through inhibition of NF-κB signaling and induction of apoptosis. It induces cell cycle arrest and apoptosis in human MDA-MB-468 breast cancer cells. It has a molecular formula of C₂₂H₂₆O₈ and a molecular weight of 418.44 g/mol.
|
| Molecular Formula |
C22H26O8
|
|---|---|
| Molecular Weight |
418.437047481537
|
| Exact Mass |
418.162
|
| CAS # |
2170228-67-6
|
| PubChem CID |
168008611
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
832
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O1C(C(=C)[C@@H]2[C@@H](CC(C=O)=CC[C@@H](C(C)=C[C@@H]12)OC(C)=O)OC(/C(=C/CO)/C)=O)=O |c:9,t:14|
|
| InChi Key |
MAIWERGSXNNKMK-NGHBZJCYSA-N
|
| InChi Code |
InChI=1S/C22H26O8/c1-12(7-8-23)21(26)29-19-10-16(11-24)5-6-17(28-15(4)25)13(2)9-18-20(19)14(3)22(27)30-18/h5,7,9,11,17-20,23H,3,6,8,10H2,1-2,4H3/b12-7+,13-9-,16-5+/t17?,18-,19?,20+/m1/s1
|
| Chemical Name |
[(3aR,6E,10Z,11aR)-9-acetyloxy-6-formyl-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (E)-4-hydroxy-2-methylbut-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (238.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3898 mL | 11.9491 mL | 23.8983 mL | |
| 5 mM | 0.4780 mL | 2.3898 mL | 4.7797 mL | |
| 10 mM | 0.2390 mL | 1.1949 mL | 2.3898 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
